Ipsen advances liver disease treatment

Beyond Biotech - the podcast from Labiotech

Jennifer Schranz is senior vice president and global head of rare diseases in the R&D division at Ipsen.

On the podcast this week, she discusses a breakthrough treatment for primary biliary cholerangitis and cholestatic liver disease.

00:56-00:49: Background information
01:44-03:21: What are primary biliary cholerangitis (PBC) and cholestatic liver disease?
03:21-03:50: How rare is PBC?
03:50-04:45: How easy is PBC diagnosis?
04:45-05:45: What are the current treatments for the condition?
05:45-07:22: What are the challenges to innovation?
07:22-08:27: What is elafibranor?
08:27-08:37: How is it administered?
08:37-09:18: Is elafibranor taken for life?
09:18-11:08: What is the ELATIVE trial, and what were the results you presented at the AASLD Liver Meeting?
11:08-13:09: What was the reaction at the meeting?
13:09-13:55: A patient-centric approach
13:55-14:44: Is a cure for PBC a possibility?
14:44-17:20: How important are acquisitions to Ipsen’s pipeline?
17:20-18:33: Working on multiple diseases
18:33-19:58: How much impact can you have on liver diseases?
19:58-21:04: What are the next steps for elafibranor?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

Chapters

1. Ipsen advances liver disease treatment (00:00:00)

2. Background information (00:00:56)

3. What are primary biliary cholerangitis (PBC) and cholestatic liver disease? (00:01:44)

4. How rare is PBC? (00:03:21)

5. How easy is PBC diagnosis? (00:03:50)

6. What are the current treatments for the condition? (00:04:45)

7. What are the challenges to innovation? (00:05:45)

8. What is elafibranor?
 (00:07:22)

9. Is elafibranor taken for life?
 (00:08:27)

10. How is elafibranor administered?
 (00:08:27)

11. What is the ELATIVE trial, and what were the results you presented at the AASLD Liver Meeting? (00:09:18)

12. What was the reaction at the meeting?
 (00:11:08)

13. A patient-centric approach
 (00:13:09)

14. Is a cure for PBC a possibility?
 (00:13:55)

15. How important are acquisitions to Ipsen’s pipeline?
 (00:14:44)

16. Working on multiple diseases
 (00:17:20)

17. How much impact can you have on liver diseases?
 (00:18:33)

18. What are the next steps for elafibranor?
 (00:19:58)